Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;34(8):10041-10055.
doi: 10.1096/fj.202000215R. Epub 2020 Jun 23.

Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep

Sonnet S Jonker  1 , George D Giraud  1   2 , Eileen I Chang  1 , Miriam R Elman  3 , Samantha Louey  1
Affiliations

Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep

Sonnet S Jonker et al. FASEB J. 2020 Aug.

Abstract

As loss of contractile function in heart disease could often be mitigated by increased cardiomyocyte number, expansion of cardiomyocyte endowment paired with increased vascular supply is a desirable therapeutic goal. Insulin-like growth factor 1 (IGF-1) administration increases fetal cardiomyocyte proliferation and heart mass, but how fetal IGF-1 treatment affects coronary growth and function is unknown. Near-term fetal sheep underwent surgical instrumentation and were studied from 127 to 134 d gestation (term = 147 d), receiving either IGF-1 LR3 or vehicle. Coronary growth and function were interrogated using pressure-flow relationships, an episode of acute hypoxia with progressive blockade of adenosine receptors and nitric oxide synthase, and by modeling the determinants of coronary flow. The main findings were that coronary conductance was preserved on a per-gram basis following IGF-1 treatment, adenosine and nitric oxide contributed to hypoxia-mediated coronary vasodilation similarly in IGF-1-treated and Control fetuses, and the relationships between coronary flow and blood oxygen contents were similar between groups. We conclude that IGF-1-stimulated fetal myocardial growth is accompanied by appropriate expansion and function of the coronary vasculature. These findings support IGF-1 as a potential strategy to increase cardiac myocyte and coronary vascular endowment at birth.

Keywords: adenosine; angiogenesis; contracture; coronary autoregulation; developmental origins; nitric oxide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The experimental timeline.
Figure 2.
Figure 2.. Coronary pressure-flow relationship example.
A pressure-flow relationship example from an IGF-1-treated fetal sheep. At day 0 (127 d gestational age [GA]) and at day 7 (134 dGA, term=147 dGA) after chronic IGF-1 treatment, autonomic responses were blocked and vascular occluders were used to transiently increase or decrease coronary driving pressure. Then a maximally-vasodilating dose of adenosine was administered to the coronary circulation, and the pressure manipulations were repeated. The slope of each relationship is the coronary conductance, and the difference between the slopes at a given pressure, on a given day, is the coronary reserve.
Figure 3.
Figure 3.. Coronary pressure-flow relationships.
The coronary conductance, normalized to weight of myocardium perfused, was not different between groups at resting “baseline” flow, or maximal hyperemia on A) day 0, or B) day 7 of IGF-1 or vehicle treatment. C) Coronary reserve was reduced within the IGF-1 group between days 0 and 7. Control n=12, IGF-1 n=8. Data were analyzed by 2-way repeated measures ANOVA followed, if justified, by the Holm-Šidák multiple comparisons test (P<0.05). Different from *same-group day 0. Data are shown as mean ± SD.
Figure 4.
Figure 4.. Blood O2 contents and coronary hemodynamics during acute hypoxia on study day 7.
A) Arterial O2 content (CaO2) in Control and IGF-1-treated fetal sheep during acute hypoxia, and with adenosine receptor (AR) and nitric oxide synthase (NOS) blockade. B) Coronary sinus O2 content (CvO2) during acute hypoxia and maximum AR and NOS blockade. C) The difference between CaO2 and CvO2, which is the O2 extracted by the myocardium. D) Coronary extraction ratio, the percent of O2 extracted from arterial blood by the myocardium. E) Coronary conductance during acute hypoxia. F) Cardiac work, calculated as the double product. G) Myocardial O2 delivered as a function of cardiac work during acute hypoxia, and with AR and NOS blockade. H) Myocardial O2 consumption, and I) myocardial O2 consumption per work. Number of animals is shown within symbols. Different from *Control, †Hypoxia timepoint within-group by the Holm-Šidák multiple comparisons test following a significant interaction term by 2-way mixed effects analysis (a symbol and bar denotes differences at this level), and significant ‡linear trend across columns (P<0.05). Data are shown as mean ± SD.
Figure 5.
Figure 5.. Example of spontaneous transient increases in circumflex coronary flow in a fetal sheep.
A LabChart window displaying (top-bottom) fetal amniotic pressure, arterial pressure (corrected for amniotic pressure), venous pressure (corrected for amniotic pressure), raw coronary flow, mean coronary flow, and heart rate in a fetus of an awake, calmly resting ewe. In this example, fetal coronary flow rises, following an elevation in amniotic compartment pressure (peak-peak interval approximately 4.5 min). Flow is elevated for approximately 11 minutes. Note that perfusion pressure and work did not change, as both arterial and venous pressures followed amniotic pressure, and heart rate did not increase. Time scale for right window, 1 division = 0.5 s; on left 1 division = 60 s.
Figure 6.
Figure 6.. O2 contents and coronary flows obtained during simultaneous sampling of arterial and coronary sinus blood, and measurements of hemodynamics.
A) The relationship between arterial O2 content (CaO2) and coronary sinus O2 content (CvO2). Coronary flow as a function of B) CaO2 and C) CvO2. D) Coronary flow as a function of the difference in between CaO2 and CvO2. Individual measurements are plotted as raw data.
See this image and copyright information in PMC

References

    1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on, E., Prevention Statistics, C., and Stroke Statistics, S. (2018) Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137, e67–e492 - PubMed
    1. Chien KR, Frisen J, Fritsche-Danielson R, Melton DA, Murry CE, and Weissman IL (2019) Regenerating the field of cardiovascular cell therapy. Nat. Biotechnol 37, 232–237 - PubMed
    1. Burrell JH, Boyn AM, Kumarasamy V, Hsieh A, Head SI, and Lumbers ER (2003) Growth and maturation of cardiac myocytes in fetal sheep in the second half of gestation. Anat. Rec. A Discov. Mol. Cell. Evol. Biol 274, 952–961 - PubMed
    1. Jonker SS, and Louey S (2016) Endocrine and other physiologic modulators of perinatal cardiomyocyte endowment. J. Endocrinol 228, R1–R18 - PMC - PubMed
    1. Jonker SS, Louey S, Giraud GD, Thornburg KL, and Faber JJ (2015) Timing of cardiomyocyte growth, maturation, and attrition in perinatal sheep. FASEB J 29, 4346–4357 - PMC - PubMed

Publication types

Substances